-
公开(公告)号:ZA955867B
公开(公告)日:1997-01-14
申请号:ZA955867
申请日:1995-07-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , MUNSCHAUER RAINER , BIALOJAN SIEGFRIED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN , DRESCHER KARLA
IPC: C07D249/08 , A61K31/41 , A61K31/435 , A61K31/4427 , A61K31/445 , A61K31/505 , A61K31/53 , A61P1/08 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D249/12 , C07D249/14 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D , A61K
Abstract: PCT No. PCT/EP95/02781 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02520 PCT Pub. Date Feb. 1, 1996The present invention relates to triazole compounds of the following formula: where R1, R2, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
公开(公告)号:FI970150A0
公开(公告)日:1997-01-14
申请号:FI970150
申请日:1997-01-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , MUNSCHAUER RAINER , BIALOJAN SIEGFRIED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN , DRESCHER KARLA
IPC: C07D239/26 , A61K31/505 , A61K31/506 , A61P25/16 , A61P25/24 , A61P25/26 , C07D239/38 , C07D239/46 , C07D239/56 , C07D239/60 , C07D401/00 , C07D401/12 , C07D
Abstract: The present invention relates to the use of pyrimidine compounds of the following formula:wherein R1, R2, R3, A, B and Ar have the meanings indicated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
公开(公告)号:FI970150A
公开(公告)日:1997-01-14
申请号:FI970150
申请日:1997-01-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , MUNSCHAUER RAINER , BIALOJAN SIEGFRIED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN , DRESCHER KARLA
IPC: C07D239/26 , A61K31/505 , A61K31/506 , A61P25/16 , A61P25/24 , A61P25/26 , C07D239/38 , C07D239/46 , C07D239/56 , C07D239/60 , C07D401/00 , C07D401/12 , C07D
Abstract: The present invention relates to the use of pyrimidine compounds of the following formula:wherein R1, R2, R3, A, B and Ar have the meanings indicated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
公开(公告)号:FI970148A
公开(公告)日:1997-01-14
申请号:FI970148
申请日:1997-01-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MUELLER BEATRICE , BACH ALFRED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN
IPC: C07D233/84 , A61K31/33 , A61K31/415 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18 , A61K
Abstract: PCT No. PCT/EP95/02782 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02246 PCT Pub. Date Feb. 1, 1996The present invention relate to the use of heterocyclic compounds of the following formula:Het-A-B-Arwhere Het, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
公开(公告)号:CA2195242A1
公开(公告)日:1996-02-01
申请号:CA2195242
申请日:1995-07-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MUELLER BEATRICE , BACH ALFRED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN
IPC: C07D233/84 , A61K31/33 , A61K31/415 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18 , A61K31/52 , A61K31/505 , A61K31/53
Abstract: The present invention relates to the use of heterocyclic compounds of formula (I) Het - A - B - Ar in which Het A, B and Ar have the meanings given in the description. The compounds of the invention have a high affinity for the dopamine-D3-receptor and are therefore usable for the treatment of diseases responding to dopamine-D3-ligands.
-
公开(公告)号:CA2195240A1
公开(公告)日:1996-02-01
申请号:CA2195240
申请日:1995-07-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MUELLER BEATRICE , BACH ALFRED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN
IPC: C07D277/22 , A61K31/425 , A61K31/426 , A61K31/433 , A61K31/435 , A61K31/44 , A61K31/4439 , A61K31/445 , A61K31/454 , A61K31/496 , A61K31/54 , C07D277/20 , C07D277/32 , C07D277/36 , C07D277/42 , C07D285/12 , C07D285/125 , C07D285/135 , C07D417/12
Abstract: The use is disclosed of thiazole and thiadiazole compounds having the formula (I), in which R1, A, B and Ar have the meanings given in the description. These compounds have a high affinity to the dopamine D3 receptor and are therefore useful for treating diseases of the central nervous system.
-
87.
公开(公告)号:MY132993A
公开(公告)日:2007-10-31
申请号:MYPI9802644
申请日:1998-06-13
Applicant: BASF AG
Inventor: BACH ALFRED , STARCK DOROTHEA DR , GARCIA-LADONA FRANCISCO-JAVIER , EMLING FRANZ , STEINER GERD DR , TESCHENDORF HANS-JURGEN , WICKE KARSTEN , DULLWEBER UTA
IPC: A61K31/495 , A61K31/505 , A61K31/519 , A61P25/00 , A61P25/24 , A61P43/00 , C07D495/14
Abstract: 3-SUBSTITUTED 3,4,S,6,7,8-HEXAHYDROPYRIDO [3',4':4,5]-THIENO[2,3-D]PYRIRNIDINE DERIVATIVES OF THE FORMULA I WHERE RL IS A HYDROGEN ATOM, A CL-C4-ALKYL GROUP, AN ACETYL GROUP, A PHENYLALKYL CL-C4 RADICAL, THE AROMATIC SYSTEM BEING UNSUBSTITUTED OR SUBSTITUTED BY HALOGEN, CL-C4-ALKYL, TRIFLUOROMETHYL, HYDROXYL, CL-C4-ALKOXY, AMINO, CYANO OR NITRO GROUPS, OR IS A PHENYLALKANONE RADICAL, IT BEING POSSIBLE FOR THE PHENYL GROUP TO BE SUBSTITUTED BY HALOGEN, R2 IS A PHENYL, PYRIDYL, PYRIMIDINYL OR PYRAZINYL GROUP WHICH IS UNSUBSTITUTED OR'MONO- OR DISUBSTITUTED BY HALOGEN ATOMS, CL-C4-ALKYL, TRIFLUOROMETHYL, TRIFLUOROMETHOXY, HYDROXYL, CL-C4- ALKOXY, AMINO, MONOMETHYLAMINO, DIMETHYLAMINO, CYANO OR NITRO GROUPS AND WHICH MAY BE FUSED TO A BENZENE NUCLEUS WHICH CAN BE UNSUBSTITUTED OR MONO- OR DISUBSTITUTED BY HALOGEN ATOMS, CL-C4 ALKYL, HYDROXYL, TRIFLUOROMETHYL, CL-C4-ALKOXY, AMINO, CYANO OR NITRO GROUPS AND MAY CONTAIN 1 NITROGEN ATOM, OR TO A 5- OR 6-MEMBERED RING WHICH MAY CONTAIN 1-2 OXYGEN ATOMS, A IS NH OR AN OXYGEN ATOM, Y IS CH2, CH2-CH2, CH2-CH2-CH2 OR CH2-CH, Z IS A NITROGEN ATOM, CARBON ATOM OR CH, IT ALSO BEING POSSIBLE FOR THE LINKAGE BETWEEN Y AND Z TO BE A DOUBLE BOND, AND N IS 2, 3 OR 4, AND THE PHYSIOLOGICALLY TOLERATED SALTS THEREOF.
-
公开(公告)号:SI9520080B
公开(公告)日:2003-02-28
申请号:SI9520080
申请日:1995-07-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , MUNSCHAUER RAINER , BIALOJAN SIEGFRIED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN , DRESCHER KARLA
IPC: C07D239/26 , A61K31/505 , A61K31/506 , A61P25/16 , A61P25/24 , A61P25/26 , C07D239/38 , C07D239/46 , C07D239/56 , C07D239/60 , C07D401/00 , C07D401/12 , A61K31/305
Abstract: The present invention relates to the use of pyrimidine compounds of the following formula:wherein R1, R2, R3, A, B and Ar have the meanings indicated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
公开(公告)号:PT772603E
公开(公告)日:2002-11-29
申请号:PT95926898
申请日:1995-07-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , MUNSCHAUER RAINER , LANSKY ANNEGRET , BIALOJAN SIEGFRIED , WICKE KARSTEN , DRESCHER KARLA
IPC: C07D239/26 , A61K31/505 , A61K31/506 , A61P25/16 , A61P25/24 , A61P25/26 , C07D239/38 , C07D239/46 , C07D239/56 , C07D239/60 , C07D401/00 , C07D401/12
Abstract: The present invention relates to the use of pyrimidine compounds of the following formula:wherein R1, R2, R3, A, B and Ar have the meanings indicated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
90.
公开(公告)号:CZ290464B6
公开(公告)日:2002-07-17
申请号:CZ443199
申请日:1998-05-29
Applicant: BASF AG
Inventor: STEINER GERD , DULLWEBER UTA , STARCK DOROTHEA , BACH ALFRED , WICKE KARSTEN , TESCHENDORF HANS-JURGEN , GARCIA-LADONA FRANCISCO-JAVIER , EMLING FRANZ
IPC: A61K31/495 , A61K31/519 , A61P25/00 , A61P25/24 , A61P43/00 , C07D495/04
Abstract: In the present invention there are disclosed 3-substituted 3,4-dihydrothieno[2,3-d]pyrimidine derivatives of the general formula I, in which Re1 and Re2 represent a hydrogen atom or an alkyl group containing 1 to 4 carbon atoms, Re3 represents a phenyl, pyridyl, pyrimidinyl or pyrazinyl group, which can be optionally mono- or disubstituted with a halogen atom or with the following groups; alkyl containing 1 to 4 carbon atoms, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy containing 1 to 4 carbon atoms, amino, monomethylamino, dimethylamino, cyano or nitro and which can be condensed with a benzene nucleus that can be optionally mono- or disubstituted with a halogen atom or with the following groups; alkyl containing 1 to 4 carbon atoms, hydroxy, trifluoromethyl, alkoxy containing 1 to 4 carbon atoms, amino, cyano or nitro and which can optionally contain 1 nitrogen atom, or with 5- or 6-membered ring that can contain 1 to 2 oxygen atoms, A represents NH or an oxygen atom, Y represents CHi2, CHi2-CHi2, CHi2-CHi2-CHi2 or CHi2-CH, Z represents a nitrogen atom, a carbon atom or CH, whereby the bond between Y and Z can be also a double bond and n is 2, 3 or 4, and their physiologically acceptable salts. The invented derivatives are intended for treating depressions and related disorders with activity as selective antagonist 5-HTi1B and 5-HTi1A.
-
-
-
-
-
-
-
-
-